Financial Consulate Inc. maintained its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,500 shares of the company’s stock at the end of the second quarter. Financial Consulate Inc. owned about 0.06% of Aerie Pharmaceuticals worth $972,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Aperio Group LLC raised its stake in Aerie Pharmaceuticals by 4.7% in the second quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock valued at $258,000 after buying an additional 219 shares during the period. Guggenheim Capital LLC raised its stake in shares of Aerie Pharmaceuticals by 4.2% in the fourth quarter. Guggenheim Capital LLC now owns 34,135 shares of the company’s stock worth $1,292,000 after buying an additional 1,384 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Aerie Pharmaceuticals by 1.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 136,106 shares of the company’s stock worth $6,173,000 after buying an additional 1,388 shares during the last quarter. First Mercantile Trust Co. raised its stake in shares of Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock worth $319,000 after buying an additional 1,620 shares during the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Aerie Pharmaceuticals by 7.5% in the first quarter. HighTower Advisors LLC now owns 27,426 shares of the company’s stock worth $1,243,000 after buying an additional 1,907 shares during the last quarter. Hedge funds and other institutional investors own 92.98% of the company’s stock.

Aerie Pharmaceuticals, Inc. (AERI) opened at 54.95 on Monday. The stock’s 50 day moving average price is $54.24 and its 200-day moving average price is $47.46. Aerie Pharmaceuticals, Inc. has a 12 month low of $16.85 and a 12 month high of $59.50. The stock’s market cap is $2.00 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.02. Equities analysts expect that Aerie Pharmaceuticals, Inc. will post ($2.57) EPS for the current year.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/07/financial-consulate-inc-has-972000-position-in-aerie-pharmaceuticals-inc-nasdaqaeri.html.

A number of brokerages have issued reports on AERI. HC Wainwright set a $69.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 1st. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research note on Friday, July 28th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 price target for the company in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $66.08.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 9.36% of the stock is owned by insiders.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.